New Regenerative Therapy for Osteoarthritis with peripheral macrophages but not stem cells
Safe and low-cost regenerative medicine for future therapy.
https://academic.oup.com/stcltm/advance-article/doi/10.1093/stcltm/szae006/7609136
Highlights
-
We found that tissue-reparing macrophage cell culture medium (M2-CM) administered intravenously into the mouse osteoarthritis (OA) model regenerated articular cartilage.
-
M2-CM inhibited cartilage degradation and promoted cartilage synthesis in OA. Our study also revealed that the central component of the therapeutic effect of M2-CM is secreted frizzled-related protein 1 (sFRP1), a Wnt signaling antagonist.
-
This study suggests the possibility of joint regeneration therapy using macrophages obtained from peripheral blood. It is expected to realize safe and low-cost regenerative medicine.
Advantages of M2-CM regenerative medicine over standard autologous bone marrow mesenchymal stem cell (MSC) transplantation.
-
MSCs must be harvested surgically, but macrophages can be harvested from peripheral blood.
-
The number and differentiation potential of MSCs decrease with age, but the number and activity of macrophages in peripheral blood do not change significantly.
-
MSCs must be removed from young individuals and stored in cell banks, which is expensive.
-
MSCs and macrophages transplanted into an inflammatory environment have low survival rates and unstable therapeutic efficacy. M2-CM produced in cell culture facilities has a stable therapeutic effect.
-
M2-CM can be allogeneically transplanted in large numbers at low cost using M2 macrophages derived from ES or iPS cells.
This study suggests the possibility of joint regenerative medicine using macrophages derived from peripheral blood. Safe and low-cost regenerative medicine is expected to be realized.